WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment

Description

The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients.

Conditions

Pancreatic Cancer, Breast Cancer

Study Overview

Study Details

Study overview

The purpose of this study is to evaluate the feasibility of using a commercial WATD (Wearable Activity Tracker Device) to collect HRV (Heart Rate Variability) data from pancreatic and breast cancer patients.

Wearable Activity Tracker Devices and Cancer-Related Fatigue: A Clinical Utility Pilot Study For Patients Undergoing Anti-Cancer Treatment

WATD and Cancer-Related Fatigue: A Study For Patients Undergoing Anti-Cancer Treatment

Condition
Pancreatic Cancer
Intervention / Treatment

-

Contacts and Locations

Charlotte

Levine Cancer Institute, Charlotte, North Carolina, United States, 28204

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Written informed consent and HIPAA authorization for release of personal health information
  • * Patients pancreatic or invasive breast cancer per enrolling investigator who is planning on or has started anti-cancer treatment. Note: Patients with cancer who are not planning to receive anti-cancer treatment are not eligible for study participation
  • * Patients with any severity of self-reported fatigue per enrolling investigator
  • * Age ≥ 18 years at the time of consent
  • * Ability to read and understand the English language
  • * As determined by the enrolling investigator, the ability of the participant to understand and comply with study procedures (i.e., completing questionnaires and device return) for the entire length of the study
  • * Any documented, clinically significant cardiac-related abnormality per enrolling investigator that could compromise the outcome of the study. NOTE: The heart rate data collected using the WATD will not be used for patient care.
  • * Other factors or conditions, per investigator discretion, for which participation in the study would not be in the patient's best interest or could interfere with study assessment results or preclude study completion
  • * No internet, Wi-Fi access or email account
  • * No access to a smartphone or mobile device

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Wake Forest University Health Sciences,

Dori Beeler, PhD, PRINCIPAL_INVESTIGATOR, Wake Forest University Health Sciences

Study Record Dates

2025-12-15